Clinical Report: Multi-Ancestry Polygenic Risk Scores for Type 2 Diabetes
Overview
Multi-ancestry polygenic risk scores (PRSs) significantly enhance the prediction of type 2 diabetes across diverse ancestry groups, outperforming traditional clinical factors. The study involved nearly 2 million participants, revealing that higher PRS values correlate with increased odds of developing diabetes and related complications.
Background
Diabetes is a major global health concern, with type 2 diabetes (T2D) posing significant morbidity and mortality risks. Traditional risk assessment methods primarily focus on clinical factors and glycemia, often neglecting genetic predispositions. The integration of polygenic risk scores into risk stratification may provide a more nuanced understanding of diabetes risk across diverse populations.
Data Highlights
Population
Odds Ratio (97.5th vs Interquartile)
African or African American
3.43
Admixed American
7.47
East Asian
6.62
European
6.25
South Asian
4.50
Key Findings
Multi-ancestry PRSs showed larger effect sizes than single-ancestry PRSs across all groups.
Odds of type 2 diabetes increased significantly with higher PRS values, particularly at the extremes of the distribution.
Predictive performance varied by ancestry, with European and East Asian populations showing the strongest discrimination.
Higher PRS values were associated with earlier onset of type 2 diabetes by up to 2.3 years.
Participants with normal glucose but high PRS had similar diabetes-free survival risks as those with elevated glucose in the lowest PRS tertile.
Clinical Implications
Incorporating multi-ancestry PRSs into clinical practice may enhance diabetes risk stratification, particularly in diverse populations. Clinicians should consider genetic risk alongside traditional factors to identify individuals at higher risk for developing type 2 diabetes and its complications.
Conclusion
The findings underscore the potential of multi-ancestry polygenic risk scores to improve diabetes risk assessment and highlight the need for further validation in clinical settings.
Acidic gum beat sugar-free at cranking out nitric oxide from beetroot juice — exactly backward from what test-tube studies predicted. Also this week: a sleep gene that ignores amyloid, and jackfruit sap moonlighting as a bone-building drug delivery system.
